Tag :

intranasal carbetocin Press Releases

Levo Therapeutics Announces Initiation of the CARE-PWS Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome

Levo Therapeutics, Inc. announced today that enrollment is underway in its Phase 3 clinical study of intranasal carbetocin (LV-101) for the treatment of Prader-Willi syndrome (PWS). The study is a multi-center, randomized, double-blind, placebo-controlled study called CARE-PWS.  “We are excited to bring…

Levo Therapeutics Announces Publication of Phase 2 Study Results and Planned Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome

​Levo Therapeutics Inc. announced today that JCI Insight has published the results of a Phase 2 study of intranasal carbetocin (LV-101) in patients with genetically confirmed Prader-Willi syndrome (PWS). Results from the study suggest that the investigational product LV-101 has marked effects on core features of PWS,…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login